- Home
- MU vs AZN Comparison
MU vs AZN Comparison
Compare MU & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MU | AZN |
|---|---|---|
| Founded | 1978 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0B | 276.3B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | MU | AZN |
|---|---|---|
| Price | $258.92 | $90.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 32 | 2 |
| Target Price | ★ $215.81 | N/A |
| AVG Volume (30 Days) | ★ 25.5M | 5.5M |
| Earning Date | 12-17-2025 | 11-06-2025 |
| Dividend Yield | 0.18% | ★ 1.71% |
| EPS Growth | ★ 984.29 | 45.02 |
| EPS | ★ 7.59 | 6.02 |
| Revenue | $37,378,000,000.00 | ★ $58,127,000,000.00 |
| Revenue This Year | $50.61 | $11.33 |
| Revenue Next Year | $16.26 | $6.08 |
| P/E Ratio | $33.26 | ★ $14.92 |
| Revenue Growth | ★ 48.85 | 13.52 |
| 52 Week Low | $61.54 | $61.24 |
| 52 Week High | $260.58 | $94.02 |
Technical Indicators
Market Signals| Indicator | MU | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 57.48 |
| Support Level | $223.33 | $89.67 |
| Resistance Level | $244.37 | $91.45 |
| Average True Range (ATR) | 11.88 | 1.42 |
| MACD | 1.46 | -0.36 |
| Stochastic Oscillator | 99.55 | 40.86 |
Price Performance
Historical ComparisonAbout MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.